Department of Disease Prevention, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
Recent Pat Antiinfect Drug Discov. 2020;15(1):75-84. doi: 10.2174/1574891X15666200604115001.
Studies showed that biogenic selenium nanoparticles (SeNPs) have a number of pharmacological properties, such as antimicrobial ones.
The present investigation assesses the efficacy of biogenic selenium nanoparticles (SeNPs) as a new patent against latent toxoplasmosis in a mice model.
Male BALB/c mice were orally treated with SeNPs at the doses of 2.5, 5, 10 mg/kg once a day for 14 days. On the 15th day, the mice were infected with the intraperitoneal inoculation of 20-25 tissue cysts from the Tehran strain of Toxoplasma gondii. The mean numbers of brain tissue cysts and the mRNA levels of TNF-α, IL-12, IL-10, IFN-γ, and inducible nitric oxide synthase (iNOS) in mice of each tested group were measured. Moreover, serum clinical chemistry factors in treated mice were examined to determine the safety of SeNPs.
The mean number of the brain tissue cysts was significantly (P<0.001) decreased in mice treated with SeNPs at doses 2.5 (n=37), 5 (n=11), and 10 mg/kg (n=3) based on a dose dependent manner compared with the control group (n=587). The mRNA levels of IFN-γ, TNF-α, IL-12, and iNO were significantly increased in mice treated with SeNPs at the doses 10 mg/kg compared with control subgroups (p<0.05). No significant variation (p>0.05) was observed in the clinical chemistry parameters among the mice in the control subgroups compared with groups treated with SeNPs.
The results of the present study showed a new patent in the treatment of toxoplasmosis; so that taking the biogenic selenium nanoparticles in concentrations of 2.5-10 mg/kg for 2 weeks was able to prevent severe symptoms of the toxoplasmosis in a mice model. This indicated the prophylactic effects of SeNPs with no considerable toxicity against latent toxoplasmosis. However, more studies are required to elucidate the correct anti-Toxoplasma mechanisms of SeNPs.
研究表明，生物源硒纳米粒子（SeNPs）具有多种药理学特性，如抗菌作用。
本研究评估生物源硒纳米粒子（SeNPs）作为一种新专利，对潜伏性弓形虫病的治疗效果，通过小鼠模型进行评估。
雄性 BALB/c 小鼠每天口服 SeNPs 剂量为 2.5、5、10mg/kg，连续 14 天。第 15 天，通过腹腔内接种 20-25 个来自德黑兰株弓形虫的组织囊，对小鼠进行感染。测量每个实验组的小鼠脑组织囊的平均数量和 TNF-α、IL-12、IL-10、IFN-γ 和诱导型一氧化氮合酶（iNOS）的 mRNA 水平。此外，还检测了治疗小鼠的血清临床化学因子，以确定 SeNPs 的安全性。
与对照组（n=587）相比，以剂量依赖的方式，用 2.5（n=37）、5（n=11）和 10mg/kg（n=3）剂量的 SeNPs 处理的小鼠，脑组织囊的平均数量显著减少（P<0.001）。与对照组亚组相比，用 10mg/kg 剂量的 SeNPs 处理的小鼠的 IFN-γ、TNF-α、IL-12 和 iNO 的 mRNA 水平显著增加（p<0.05）。与用 SeNPs 处理的小鼠相比，对照组小鼠的临床化学参数没有明显变化（p>0.05）。
本研究结果显示了一种治疗弓形虫病的新专利；因此，在小鼠模型中，连续 2 周以 2.5-10mg/kg 的浓度服用生物源硒纳米粒子能够预防严重的弓形虫病症状。这表明 SeNPs 具有预防作用，对潜伏性弓形虫病没有明显的毒性。然而，还需要更多的研究来阐明 SeNPs 对抗弓形虫的确切机制。
